The next leg of a huge share-price rally for Belgium’s UCB — driven by the success of its Bimzelx skin disease medicine — hinges on key results for a rival drug https://t.co/aQrLC6Ddkf ...

CEO Jean-Christophe Tellier said the success of UCB's skin disease drug Bimzelx will allow the company to keep investing in the development pipeline https://t.co/T047nbOOym ...